MorphoSys seizes FOMC glee to get €84m and zero discount

German biotechnology firm MorphoSys raised €84m through a sale of new shares on Wednesday night. Pre-sounding gave bankers the confidence to launch the deal before any statements from Wednesday's Federal Open Market Committee meetings in the US, but the positive market reaction to the news later that the Fed was not looking to reduce its bond-buying programme immediately helped the deal to price with no discount.